Long-Term Protection from Malaria Linked to Antibodies
Author Information
Author(s): Roussilhon Christian, Oeuvray Claude, Müller-Graf Christine, Tall Adama, Rogier Christophe, Trape Jean-François, Theisen Michael, Balde Aissatou, Pérignon Jean-Louis, Druilhe Pierre
Primary Institution: Institut Pasteur, Paris, France
Hypothesis
Is there a relationship between antibody responses to malaria vaccine candidates and clinical protection in humans?
Conclusion
The study found that IgG3 antibodies to merozoite surface protein 3 are strongly associated with clinical protection against malaria.
Supporting Evidence
- Only IgG3 antibodies to MSP3 were significantly associated with protection against malaria.
- Children developed protection against malaria when they were very young.
- Antibodies can be elicited by vaccination early in life.
Takeaway
Kids who have special antibodies can fight off malaria better, and these antibodies can be made through vaccines.
Methodology
The study analyzed antibody responses in relation to malaria protection in a village in Senegal over six years.
Limitations
The findings may not apply to areas with lower malaria transmission rates.
Participant Demographics
The study included 217 participants from Dielmo, Senegal, with 96 children and 121 older adolescents and adults.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 74.5%–82.0%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website